Finance

Lists
Q3 2026 earnings • released • EPS beat +7,77% • Revenue beat +2,95%
See results
GH:NASDAQ
Guardant Health Inc
USD 149,16
-2,79%
(-4,27) 1D
6 Nov., 13:23:11 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GH...
Open
USD 141,83
High
USD 151,81
Low
USD 136,42
Mkt. cap
20,02 mjd
Avg. vol.
1,86 m
Volume
3,47 m
52-wk high
USD 191,01
52-wk low
USD 74,55
EPS
-USD 3,50
Beta
1,67
Shares outstanding
134,20 m
No. of employees
2 k
Open
USD 141,83
High
USD 151,81
Low
USD 136,42
Mkt. cap
20,02 mjd
Avg. vol.
1,86 m
Volume
3,47 m
52-wk high
USD 191,01
52-wk low
USD 74,55
EPS
-USD 3,50
Beta
1,67
Shares outstanding
134,20 m
No. of employees
2 k
News stories
From web sources and news partners
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees2,5 k
Founded2012
HeadquartersPalo Alto, Kalifornië, Verenigde State van Amerika
SectorHealth Care
IndustryHealth care provider
Websiteguardanthealth.com
Analyst ratings
Based on 18 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
18
Hold
0
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current USD 149,16
USD 225,00 (+50,85%)
Average
USD 205,44 (+37,74%)
Lowest
USD 193,00 (+29,40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Dan Leonard
RBC Capital
Buy
Maintained
USD 200,00
+34,1%
11/06/2026
Daniel Brennan
TD Cowen
Buy
Maintained
USD 220,00
+47,5%
11/06/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
USD 196,00
+31,4%
11/06/2026
Luke Sergott
Barclays
Buy
Maintained
USD 220,00
+47,5%
11/06/2026
David Westenberg
Piper Sandler
Buy
Maintained
USD 193,00
+29,4%
11/06/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
USD 210,00
+40,8%
11/06/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
USD 205,00
+37,4%
11/06/2026
Mark Massaro
BTIG
Buy
Maintained
USD 210,00
+40,8%
10/27/2026
Max Masucci
Roth MKM
Buy
Initiated
USD 200,00
+34,1%
10/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
USD 200,00
+34,1%
10/20/2026
Eve Burstein
Bernstein
Buy
Reiterated
USD 210,00
+40,8%
10/19/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
USD 195,00
+30,7%
10/14/2026
Lu Li
Bank of America Securities
Buy
Maintained
USD 200,00
+34,1%
10/09/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
USD 200,00
+34,1%
10/09/2026
Subbu Nambi
Guggenheim
Buy
Maintained
USD 200,00
+34,1%
10/01/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
USD 225,00
+50,8%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
USD 225,00
+50,8%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
USD 203,00
+36,1%
09/08/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/08/2026
Bradley Bowers
Mizuho Securities
Buy
Maintained
USD 200,00
+34,1%
08/04/2026
Mason Carrico
Stephens
Buy
Maintained
USD 195,00
+30,7%
08/04/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
USD 180,00
+20,7%
08/03/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
USD 125,00
-16,2%
07/29/2026
Patrick B Donnelly
Citi
Buy
Maintained
USD 215,00
+44,1%
07/08/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
USD 200,00
+34,1%
07/06/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
USD 150,00
+0,6%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
USD 150,00
+0,6%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/27/2026
Andrew Cooper
Raymond James
Buy
Reiterated
USD 129,00
-13,5%
02/23/2026
Last report
05 Nov. 2026
Fiscal period
Q3 2026
-USD 0,29 / -USD 0,31
+7,77%beat
Revenue / Est. (USD)
360,98 m / 350,64 m
+2,95%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
265,20 m
281,27 m
301,66 m
334,98 m
Cost of goods sold
93,59 m
99,49 m
104,92 m
115,95 m
Cost of revenue
93,59 m
99,49 m
104,92 m
115,95 m
Research and development expenses
89,96 m
98,26 m
91,04 m
96,53 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
180,53 m
204,20 m
227,06 m
250,61 m
Operating expense
270,48 m
302,46 m
318,10 m
347,15 m
Total operating expenses
364,07 m
401,96 m
423,02 m
463,10 m
Operating income
-98,87 m
-120,69 m
-121,35 m
-128,12 m
Other non operating income
-48,00 k
-4,69 m
1,55 m
308,00 k
EBT including unusual items
-92,59 m
-130,22 m
-111,70 m
-119,96 m
EBT excluding unusual items
-92,47 m
-116,52 m
-111,70 m
-118,96 m
Income tax expense
136,00 k
-1,73 m
372,00 k
185,00 k
Effective tax rate
-0,15%
1,33%
-0,33%
-0,15%
Other operating expenses
-
-
-
-
Net income
-92,72 m
-128,49 m
-112,08 m
-120,14 m
Net profit margin
-34,96%
-45,68%
-37,15%
-35,87%
Earnings per share
-0,39
-0,50
-0,45
-0,42
Interest and investment income
7,39 m
10,03 m
11,15 m
10,20 m
Interest expense
-943,00 k
-1,18 m
-3,05 m
-1,35 m
Net interest expenses
6,45 m
8,85 m
8,10 m
8,85 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-89,47 m
-110,64 m
-111,91 m
-118,56 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme